Investor directory

Cleveland Biolabs

Cleveland BioLabs, Inc. is a biopharmaceutical company focused on developing innovative treatments to activate the immune system and address significant medical challenges, particularly in oncology and radiation protection. Established in 2003 and based in Buffalo, New York, the company utilizes its proprietary platform of toll-like receptor (TLR) activators to create products aimed at mitigating radiation injuries and enhancing cancer therapies. Its lead product candidate, entolimod, serves as an immune-stimulatory agent for both radiation countermeasures and various oncology applications. Additionally, Cleveland BioLabs is developing Mobilan, a recombinant non-replicating adenovirus that targets TLR5. The company collaborates with esteemed institutions such as the Cleveland Clinic and Roswell Park Cancer Institute to advance its research and development initiatives.
http://www.cbiolabs.com
https://crunchbase.com/organization/cleveland-biolabs
https://facebook.com/111316298918695
https://linkedin.com/company/cleveland-biolabs
https://pitchbook.com/profiles/company/41591-98
https://twitter.com/clevelandbiolab
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=21826171

Alexander Shakhov

Director

2 past transactions

Panacela Labs

Series B in 2015
Panacela Labs, Inc. is a joint venture established in 2011, primarily focused on developing gene therapy drugs for cancer and infectious diseases. The company is a collaboration between Cleveland BioLabs, a clinical-stage biotechnology firm, and RUSNANO, a major Russian investment entity, along with key partnerships with renowned institutions such as Roswell Park Cancer Institute, Children’s Cancer Institute of Australia, and Cleveland Clinic Foundation. With a majority ownership of 54.6% held by Cleveland BioLabs, Panacela Labs operates from the Innovation Center "Skolkovo." The company's therapeutic innovations aim to enhance cancer immunotherapy, improve chemotherapy efficacy, and provide targeted treatments for prostate cancer and other conditions, ultimately striving to improve patient outcomes and quality of life.

Panacela Labs

Series A in 2011
Panacela Labs, Inc. is a joint venture established in 2011, primarily focused on developing gene therapy drugs for cancer and infectious diseases. The company is a collaboration between Cleveland BioLabs, a clinical-stage biotechnology firm, and RUSNANO, a major Russian investment entity, along with key partnerships with renowned institutions such as Roswell Park Cancer Institute, Children’s Cancer Institute of Australia, and Cleveland Clinic Foundation. With a majority ownership of 54.6% held by Cleveland BioLabs, Panacela Labs operates from the Innovation Center "Skolkovo." The company's therapeutic innovations aim to enhance cancer immunotherapy, improve chemotherapy efficacy, and provide targeted treatments for prostate cancer and other conditions, ultimately striving to improve patient outcomes and quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.